Literature DB >> 3009960

[Alpha 1-antitrypsin deficiency: a review with special reference to the significance of heterozygous deficiency].

M Schneider, G Pott, U Gerlach.   

Abstract

Homozygous deficiency of alpha-1 antitrypsin is the most common inborn error or metabolism in Europe. Severe deficiency of this major protease inhibitor in serum is associated with chronic obstructive lung disease, chronic liver disease in adults and neonatal hepatitis. An overview is given of the role of heredity, and the diagnostic criteria and clinical and histological findings in this disorder. Emphysema seems to be caused by the free elastolytic activity of white cells, leading to the degradation of elastin. The pathophysiology of liver disease - less well understood - is discussed with special emphasis on the importance of heterozygous alpha-1 antitrypsin deficiency. Exogenous noxae seem to play an important role in the pathogenesis of heterozygous deficiency. In view of the 7% frequency of heterozygous alpha-1 antitrypsin deficiency in the European population and the role of noxae in the development of pulmonary and liver diseases, improved prophylaxis is mandatory.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009960     DOI: 10.1007/bf01711647

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  63 in total

1.  Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site.

Authors:  K Nakajima; J C Powers; B M Ashe; M Zimmerman
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

2.  Alpha1 antitrypsin deficiency in chronic liver disease, and a report of cirrhosis and emphysema in adult members of a family.

Authors:  P Kumar; M Lancaster-Smith; P Cook; A Stansfeld; M L Clark; A M Dawson
Journal:  Br Med J       Date:  1974-03-02

3.  Heterozygous and homozygous alpha1-antitrypsin deficiency in patients with pulmonary emphysema.

Authors:  J Lieberman
Journal:  N Engl J Med       Date:  1969-08-07       Impact factor: 91.245

4.  Deficiency of alpha-antitrypsin in childhood liver disease.

Authors:  A M Johnson; C A Alper
Journal:  Pediatrics       Date:  1970-12       Impact factor: 7.124

5.  Properties of isolated human alpha1-antitrypsins of Pi types M, S and Z.

Authors:  J O Jeppsson; C B Laurell; M Fagerhol
Journal:  Eur J Biochem       Date:  1978-02-01

6.  An in vitro study of the influence of plasma protease inhibitors and aprotinin on trypsin-induced C3 cleavage in human serum.

Authors:  A Lasson; K Ohlsson
Journal:  Biochim Biophys Acta       Date:  1982-12-20

7.  Proteases and protease inhibitors in chronic obstructive lung disease.

Authors:  S Erikson
Journal:  Acta Med Scand       Date:  1978

8.  Kinetics of the inhibition of leukocyte elastase by the bronchial inhibitor.

Authors:  F Gauthier; U Fryksmark; K Ohlsson; J G Bieth
Journal:  Biochim Biophys Acta       Date:  1982-01-18

9.  An immunocytochemical study of the distribution of lysozyme, a1-antitrypsin and a1-antichymotrypsin in the normal and pathological gall bladder.

Authors:  K Aroni; C Kittas; C S Papadimitriou; N X Papacharalampous
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

10.  Transport of proteases across neonatal intestine and development of liver disease in infants with alpha-1 antitrypsin deficiency.

Authors:  J N Udall; K J Bloch; W A Walker
Journal:  Lancet       Date:  1982-06-26       Impact factor: 79.321

View more
  2 in total

Review 1.  Aetiology and pathophysiology of chronic liver disorders.

Authors:  J Schölmerich; A Holstege
Journal:  Drugs       Date:  1990       Impact factor: 9.546

2.  Alpha 1-antitrypsin and survival in hepatocellular carcinoma.

Authors:  A Tzonou; L Sparos; V Kalapothaki; X Zavitsanos; A Rebelakos; D Trichopoulos
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.